JP2012511026A - 抗脂抗体結晶構造を用いた抗体設計 - Google Patents

抗脂抗体結晶構造を用いた抗体設計 Download PDF

Info

Publication number
JP2012511026A
JP2012511026A JP2011539761A JP2011539761A JP2012511026A JP 2012511026 A JP2012511026 A JP 2012511026A JP 2011539761 A JP2011539761 A JP 2011539761A JP 2011539761 A JP2011539761 A JP 2011539761A JP 2012511026 A JP2012511026 A JP 2012511026A
Authority
JP
Japan
Prior art keywords
antibody
lipid
fragment
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511026A5 (enExample
Inventor
エイ． サバディニ ロジャー
ジョナサン ウォジシャック マイケル
ハックスフォード トム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollo Endosurgery Inc
Original Assignee
Apollo Endosurgery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apollo Endosurgery Inc filed Critical Apollo Endosurgery Inc
Publication of JP2012511026A publication Critical patent/JP2012511026A/ja
Publication of JP2012511026A5 publication Critical patent/JP2012511026A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011539761A 2008-12-05 2009-12-04 抗脂抗体結晶構造を用いた抗体設計 Pending JP2012511026A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12031808P 2008-12-05 2008-12-05
US61/120,318 2008-12-05
US15589509P 2009-02-26 2009-02-26
US61/155,895 2009-02-26
US23125809P 2009-08-04 2009-08-04
US61/231,258 2009-08-04
PCT/US2009/066862 WO2010065921A2 (en) 2008-12-05 2009-12-04 Antibody design using anti-lipid antibody crystal structures

Publications (2)

Publication Number Publication Date
JP2012511026A true JP2012511026A (ja) 2012-05-17
JP2012511026A5 JP2012511026A5 (enExample) 2012-06-28

Family

ID=42233904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011539761A Pending JP2012511026A (ja) 2008-12-05 2009-12-04 抗脂抗体結晶構造を用いた抗体設計

Country Status (9)

Country Link
US (1) US20110044990A1 (enExample)
EP (1) EP2374001A4 (enExample)
JP (1) JP2012511026A (enExample)
KR (1) KR20110097923A (enExample)
CN (1) CN102573905A (enExample)
AU (1) AU2009322185A1 (enExample)
CA (1) CA2745436A1 (enExample)
IL (1) IL213358A0 (enExample)
WO (1) WO2010065921A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9880167B2 (en) 2012-08-07 2018-01-30 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
WO2018052131A1 (ja) * 2016-09-16 2018-03-22 国立大学法人大阪大学 免疫実体クラスタリングソフトウェア
US10519220B2 (en) 2014-02-11 2019-12-31 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153416A2 (en) * 2010-06-04 2011-12-08 Lpath, Inc. Novel anti-s1p antibody variants of lt1009
ITRM20100441A1 (it) * 2010-08-05 2012-02-06 Michele Pitaro Procedimento per la produzione di anticorpi monoclonali anti-idiotipo ad uso diagnostico e/o terapeutico
CA3003397A1 (en) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
CN106916227B (zh) * 2015-12-24 2019-12-13 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
CN107480360B (zh) * 2017-08-03 2020-04-24 中北大学 光束细分和相界面漫反射的激光烧熔的数值计算方法
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0626012B1 (en) * 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
JP4460155B2 (ja) * 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
WO1999045959A1 (en) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
ATE477273T1 (de) * 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US6858383B2 (en) * 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2623517A1 (en) * 2005-09-23 2007-04-05 Walter Reed Army Institute Of Research (Wrair) Antibodies with simultaneous subsite specificities to protein and lipid epitopes
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
PT2087002E (pt) * 2006-10-27 2014-11-26 Lpath Inc Composições e métodos para a ligação de esfingosina-1- fosfato

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9880167B2 (en) 2012-08-07 2018-01-30 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
US10519220B2 (en) 2014-02-11 2019-12-31 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
US11421018B2 (en) 2014-02-11 2022-08-23 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
WO2018052131A1 (ja) * 2016-09-16 2018-03-22 国立大学法人大阪大学 免疫実体クラスタリングソフトウェア
JPWO2018052131A1 (ja) * 2016-09-16 2019-08-08 国立大学法人大阪大学 免疫実体クラスタリングソフトウェア

Also Published As

Publication number Publication date
WO2010065921A2 (en) 2010-06-10
KR20110097923A (ko) 2011-08-31
US20110044990A1 (en) 2011-02-24
WO2010065921A3 (en) 2011-12-29
EP2374001A4 (en) 2013-03-13
CA2745436A1 (en) 2010-06-10
EP2374001A2 (en) 2011-10-12
CN102573905A (zh) 2012-07-11
IL213358A0 (en) 2011-07-31
AU2009322185A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
US8026342B2 (en) Compositions and methods for binding sphingosine-1-phosphate
JP5732182B2 (ja) 眼疾患と症状を処置するための組成物および方法
US20100292443A1 (en) Humanized platelet activating factor antibody design using anti-lipid antibody templates
JP5989299B2 (ja) リゾホスファチジン酸結合のための組成物と方法
US9163091B2 (en) Compositions and methods for binding lysophosphatidic acid
JP2012511026A (ja) 抗脂抗体結晶構造を用いた抗体設計
US8604172B2 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
US20130261287A1 (en) Antibody design using anti-lipid antibody crystal structures
US8361465B2 (en) Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
AU2013273727A1 (en) Compositions and methods for treating ocular diseases and conditions
WO2011153416A2 (en) Novel anti-s1p antibody variants of lt1009
WO2012057877A2 (en) Combinations of anti-s1p antibodies and sphingolipid pathway inhibitors
US20120034631A1 (en) Anti-lysophospholipid antibody design using antibody structures
AU2016204486A1 (en) Composition and Methods for Treating Ocular Diseases and Conditions
HK1128704B (en) Compositions and methods for binding sphingosine-1-phosphate
HK1128704A (en) Compositions and methods for binding sphingosine-1-phosphate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120326

A59 Written plea

Free format text: JAPANESE INTERMEDIATE CODE: A59

Effective date: 20120326

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20120704